
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX

Fundamental Analysis


Revenue & Expenses Breakdown
Amylyx Pharmaceuticals Inc
Balance Sheet Decomposition
Amylyx Pharmaceuticals Inc
Current Assets | 216.1m |
Cash & Short-Term Investments | 204.1m |
Receivables | 300k |
Other Current Assets | 11.8m |
Non-Current Assets | 3.5m |
PP&E | 2.1m |
Other Non-Current Assets | 1.5m |
Free Cash Flow Analysis
Amylyx Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Amylyx Pharmaceuticals Inc
Revenue
|
-607k
USD
|
Cost of Revenue
|
-8.2m
USD
|
Gross Profit
|
-8.8m
USD
|
Operating Expenses
|
-221.6m
USD
|
Operating Income
|
-230.4m
USD
|
Other Expenses
|
11.5m
USD
|
Net Income
|
-218.9m
USD
|
AMLX Profitability Score
Profitability Due Diligence
Amylyx Pharmaceuticals Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Score
Amylyx Pharmaceuticals Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
AMLX Solvency Score
Solvency Due Diligence
Amylyx Pharmaceuticals Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

Score
Amylyx Pharmaceuticals Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AMLX Price Targets Summary
Amylyx Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
AMLX
is 11.86 USD
with a low forecast of 8.08 USD and a high forecast of 17.85 USD.
Dividends
Current shareholder yield for AMLX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?